{"pmid": "11986207", "sentences": {"sent_1": {"Section": "", "text": "Ninety - three patients received alemtuzumab in 21 centers worldwide , with the aim to obtain an overall response rate of at least 20 % .", "entities": {"entity_1": {"text": "alemtuzumab", "class": "Intervention", "negation": 0, "UMLS": "C0383429:alemtuzumab,", "index": 1, "start": 5}, "entity_2": {"text": "overall response rate", "class": "Outcome", "negation": 0, "UMLS": "C1704632:response,", "index": 2, "start": 17}}, "relations": {}}, "sent_2": {"Section": "", "text": "Dosage was increased gradually ( target 30 mg , 3 times weekly , for a maximum of 12 weeks ) .", "entities": {"attribute_1": {"text": "increased gradually", "class": "modifier", "negation": 0, "UMLS": "", "index": 1, "start": 2}, "attribute_2": {"text": "gradually", "class": "modifier", "negation": 0, "UMLS": "", "index": 2, "start": 3}}, "relations": {}}, "sent_3": {"Section": "", "text": "Infection prophylaxis was mandatory , beginning on day 8 , and continuing for a minimum of 2 months after treatment .", "entities": {"entity_3": {"text": "Infection prophylaxis", "class": "Outcome", "negation": 0, "UMLS": "C0877629:Infection prophylaxis,", "index": 1, "start": 0}}, "relations": {}}, "sent_4": {"Section": "", "text": "Responses were assessed at weeks 4 , 8 , and 12 , and patients were followed for 34 months .", "entities": {"entity_4": {"text": "Responses", "class": "Outcome", "negation": 0, "UMLS": "C1704632:Response,", "index": 1, "start": 0}}, "relations": {}}}}